A Simple RP-HPLC Method Development and Validation for the Simultaneous Estimation of Naproxen and Rabeprazole

Mohammad Firoz Khan, Shaila Sharmin Zuthi, Md. Shahidulla Kayser, Md. Shariful Islam, Sharmeen Asad, Mohammad A. Rashid*

Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh. 2Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka, Bangladesh.

ARTICLE INFO

Article history:
Received on: 06/10/2016
Revised on: 29/10/2016
Accepted on: 06/11/2016
Available online: 29/11/2016

Key words: Naproxen, Rabeprazole sodium, Retention time, Sample stability.

ABSTRACT

A simple, economic, selective, accurate, precise reverse phase high performance liquid chromatographic method for the simultaneous estimation of naproxen and rabeprazole sodium in pure and pharmaceutical dosage forms was developed and validated. Naproxen and rabeprazole sodium were well separated using a phenomenon ODS C18 column of dimension 4.6 mm x 250 mm, 10 µm and mobile phase comprised of sodium dihydrogen phosphate buffer (pH 7.5±0.1) and acetonitrile in the ratio of 70:30 (v/v) at the flow rate 1 mL/min and the detection was performed at 275nm. The retention time for naproxen and rabeprazole sodium were found to be 3.33 ± 0.027 and 7.61 ± 0.043 min, respectively. The developed method was validated for specificity, linearity, precision and accuracy according to ICH guidelines. The proposed method is highly specific and linear over the concentration range of 2.0-60.0 µg/mL and 1.0-30.2 µg/mL for naproxen and rabeprazole sodium, respectively. The intraday precision (% RSD) of naproxen and rabeprazole sodium was in the range of 0.39 - 1.88% and 0.20 -1.51% while the interday precision ranged from 0.08 - 1.34% and 0.73 -0.87%, respectively. The accuracy (in terms of recover) of the method varied from 99.4-104.2% and 98.1-100.6% for naproxen and rabeprazole sodium, respectively. The LOD and LOQ of naproxen and rabeprazole sodium were found to be 0.6 and 0.1 µg/mL and 1.7 and 0.4 µg/mL, respectively. The sample solutions were stable for at least three hours. However, the developed method was successfully applied to assay naproxen and rabeprazole sodium brands available in Bangladesh.

INTRODUCTION

Naproxen (Figure 1A) is a class of 2-arylpropionic acid derivatives of NSAIDs. It possesses analgesic, anti-inflammatory and antipyretic activities by inhibiting the biosynthesis of prostaglandins (Brogden et al., 1975). This drug is used for the management of rheumatoid arthritis, osteoarthritis, juvenile arthritis, ankylosing spondylitis, tendonitis, bursitis and acute gout. It poses lower adverse effects and comparable efficacy to aspirin and indomethacin (Brunton et al., 2005). Rabeprazole (Figure 1B) is a proton pump inhibitor that covalently binds and inactivates the gastric parietal cell proton pump (H+/K+ ATPase). It has efficacy in healing, symptom relief and prevention of relapse of gastric ulcer, duodenal ulcer and gastro-oesophageal reflux disease. Naproxen poses a risk of stomach ulcers (Richy et al., 2004) and hence, to reduce stomach ulceration risk, it is often prescribed along with a proton-pump inhibitor such as rabeprazole during long-term treatment of those with pre-existing stomach ulcers or a history of developing stomach ulcers (Rossi, 2013; BNF, 2013). Fewer analytical techniques like HPTLC, RP-HPLC and UV spectrophotometric methods for the estimation of naproxen in presence of proton pump inhibitoirs (PPIs) such as pantoprazole or esomeprazole (Patil and Mulla, 2013; Jain et al., 2011; Sloka et al., 2011; Jain et al., 2011) were reported earlier. While analytical methods including spectrophotometric methods (Ramesh et al., 2011; Gopi Raju et al., 2012), LC method (Asfak et al., 2007) and HPLC methods (Rao et al., 2012; Nayak et al., 2010; Saikiran et al., 2014) were reported to determine rabeprazole in presence of aceclofenac or diclofenac.
According to the information collected from the literature, there is no reported method for the simultaneous estimation of naproxen and rabeprazole in pharmaceutical dosage form. Although the combine dosage form of naproxen and rabeprazole is not available yet, so in the present work as part of our continuous research investigations (Tanam et al., 2014), we are focused on to develop and validate an optimum chromatographic condition for the simultaneous determination of naproxen and rabeprazole in a synthetic mixture. The developed method could be applied for the quality control of pharmaceutical dosage form whenever it will be available in the market or could be used to assay the naproxen and rabeprazole sodium simultaneously which will reduce the analysis time and cost significantly. However, the developed method was applied successfully to assay synthetic mixture of naproxen and rabeprazole sodium prepared from the marketed naproxen and rabeprazole sodium brands available in Bangladesh.

Fig. 1: Chemical structure of (A) naproxen and (B) rabeprazole.

MATERIALS AND METHODS

Drugs and reagents

Rabeprazole sodium and naproxen were kind gift of Advanced Chemical Industries (ACI) Ltd., Bangladesh. HPLC grade acetonitrile was obtained from Fisher Scientific Company, UK. Sodium dihydrogen phosphate, disodium hydrogen phosphate and other reagents were of analytical grade and used without further purification. A Milli-Q® (Millipore, France) water purification system was used to obtain purified water for the HPLC analysis.

Instrumentation

HPLC system (Shimadzu-UFLC Prominence) (Model-SCL 10Avp) equipped with a manual injector of 20 µL loop and UV-Visible detector (Model-SPD 10Avp) was used for the analysis. The data was recorded using LC solutions software (Version 1.03 SP3, Shimadzu Corporation, Kyoto, Japan). Phenomenex C₁₈ (4.6 mm x 250 mm; 10 µm) analytical column was used for the analysis.

Preparation of mobile phase

0.471gm of sodium phosphate monobasic and 0.863gm dibasic sodium phosphate was dissolved in 300 ml of mili-Q water. The undissolved solid was sonicated for about 5 minutes to get clear solution. Then mili-Q water was added for up to 1000 mL. Then the pH was adjusted to 7.5±0.1 with potassium hydroxide solution. Now, the mixture of buffer and acetonitrile were mixed at the ratio of 70:30 (v/v) and filtered through 0.45 µm membrane filter and degassed by sonication. This mixture was then used as mobile phase and diluent.

Standard preparation

Standard stock solution

To prepare standard stock solution, 100 mg of each drug was weighted and dissolved separately with diluents in 100 mL volumetric flask to get the final concentration of 1000 μg/mL.

Working standard solution

Working standard solutions were prepared by appropriately diluting the standard stock solution.

Analytical method validation

The experiments for analytical method validation were carried out by following ICH guidelines (International Conference on Harmonisation (ICH), 2005).

System suitability

The suitability of the system was checked by injecting one blank followed by six replicate analysis of solution containing 10 μg/mL of rabeprazole sodium and 20 μg/mL of naproxen. To ascertain the system suitability for the proposed method the retention time, theoretical plate number, peak asymmetry, resolution, capacity and selectivity factor were taken.

Specificity

The specificity of the method was tested by comparing the chromatogram obtained after injecting the diluent, standard solution of naproxen, standard solution of rabeprazole and sample solution of naproxen & rabeprazole.

Linearity and range

The linearity graphs were obtained over the concentration range of 2.0-60.0 μg/mL and 1.0-30.2 μg/mL for naproxen and rabeprazole sodium, respectively. Method of least square analysis was performed to obtain the slope, intercept, correlation coefficient (R²) and regression equation of the method.
Precision

Precision of the assay was assessed with respect to repeatability (intraday) and intermediate precision (interday). The precision of the current method was determined by analyzing three different concentrations. Three replicate of each concentration is used to calculate the relative standard deviation (RSD) by following equation below:

\[
\text{RSD (\%)} = \frac{\text{Standard deviation}}{\text{Mean}} \times 100
\]

The RSD value of ≤ 2% indicates that the method is adequately precised.

Accuracy

It measures the bias of the method. Five different concentrations of standard naproxen and rabeprazole sodium solution were used to find the accuracy of the method. Triplicate injections of each concentration were made and mean peak area was taken to calculate the concentration and the accuracy of proposed method was obtained by the following equation:

\[
\text{Accuracy (\%)} = \frac{\text{Measured concentration}}{\text{Nominal concentration}} \times 100
\]

Limit of detection (LOD)

LOD means the lowest amount of analyte in a sample that can be detected but cannot be quantified precisely, under the defined environmental conditions. The LOD was estimated by the following equation:

\[
\text{LOD} = \frac{3.3 \times \text{SD}}{\sigma}
\]

Where, SD = standard deviation of response

\[
\sigma = \text{slope of regression line}
\]

Limit of quantification (LOQ)

The LOQ is the lowest concentration of analyte in a specimen that can be determined with suitable precision and accuracy under the defined experimental conditions. The LOQ was calculated by the following equation:

\[
\text{LOQ} = \frac{10 \times \text{SD}}{\sigma}
\]

Where, SD = standard deviation of response

\[
\sigma = \text{slope of regression line}
\]

Stability of sample solution

The sample solution was analyzed for up to three hours to find the stability of the sample solution.

Application of the developed method

As combined dosage form of naproxen and rabeprazole sodium is not available in the market so we prepare synthetic mixture of naproxen and rabeprazole sodium. We purchased four (4) naproxen and three (3) rabeprazole sodium brands (tablet dosage form) available in Bangladesh. The naproxen and rabeprazole sodium brands are then coded as N1, N2, N3, N4 and R1, R2, R3, respectively (Table 1). For preparing the sample solution each drug was grounded and powder equivalent to 100 mg of each drug was taken in a 100 mL volumetric flask, dissolved in diluent, shaken and sonicated for about 20 minutes and diluted up to the mark with diluent. Then the solution was filtered through 0.45 µm membrane filter. The filtered solution was further diluted according to the need. Then the sample solutions of different brands were mixed randomly to get the synthetic mixture solutions having concentration of 20 µg/mL naproxen and 10 µg/mL rabeprazole sodium.

RESULTS AND DISCUSSION

HPLC method is one of the most powerful analytical tools in quality control department of Pharmaceutical Industry for its selectivity, sensitivity and reproducibility. The goal of this work was to develop and validate a simple, rapid and sensitive assay method for the simultaneous estimation of naproxen and rabeprazole sodium in Pharmaceutical dosage form. Chromatographic conditions, especially the composition and nature of the mobile phase, were optimized through several trials to achieve the best resolution and increase the signal of naproxen and rabeprazole sodium. Using the optimized chromatographic conditions, the HPLC method was evaluated in terms of specificity, linearity, precision, accuracy, limit of detection and limit of quantification. A good separation was achieved using a phenomenex ODS C18 column of dimension 4.6 mm × 250 mm, 10 µm and mobile phase consisting of sodium dihydrogen phosphate buffer (pH 7.5±0.1) and acetonitrile in the ratio of 70:30 (v/v) at room temperature. The flow rate was 1 mL/min and the detection was carried out at 275 nm.

System suitability

System suitability was conducted to ascertain the effectiveness of the chromatographic system. For this reason certain system suitability test parameters such as retention time, number of theoretical plates, tailing factor or peak asymmetry, resolution, capacity factor (k) and selectivity factor (α) were checked by repetitively injecting the drug solutions and results have been presented in Table 2.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Naproxen</th>
<th>Rabeprazole sodium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retention time (min)</td>
<td>3.36 ± 0.022</td>
<td>7.58 ± 0.020</td>
</tr>
<tr>
<td>Number of theoretical plate</td>
<td>6404 ± 224.9</td>
<td>9316 ± 203.2</td>
</tr>
<tr>
<td>Tailing factor</td>
<td>1.29 ± 0.08</td>
<td>1.17 ± 0.03</td>
</tr>
<tr>
<td>Capacity factor (k)</td>
<td>0.60 ± 0.006</td>
<td>2.66 ± 0.025</td>
</tr>
<tr>
<td>Resolution</td>
<td>17.77 ± 0.239</td>
<td></td>
</tr>
<tr>
<td>Selectivity factor (α)</td>
<td>4.42 ± 0.008</td>
<td></td>
</tr>
</tbody>
</table>

* Each value is the mean ± SD of six determinations.
Specificity

The specificity of the method were assessed by comparing chromatograms of a diluent, diluent spiked with naproxen, diluent spiked with rabeprazole sodium and sample solution of naproxen and rabeprazole sodium (Figure 2). The retention times were 3.33 ± 0.027 and 7.61 ± 0.043 min for naproxen and rabeprazole sodium, respectively. As shown in the figures, there were no interfering peaks observed at the elution time of naproxen and rabeprazole sodium. Therefore, the method exhibited good specificity and selectivity.

Fig. 2: Chromatogram of (A) diluent, (B) diluent spiked with Naproxen, (C) diluent spiked with Rabeprazole sodium and (D) sample solution of Rabeprazole sodium and Naproxen.
The intraday precision (% RSD) of naproxen and rabeprazole sodium, respectively (Table 3).

When average peak area (y) was plotted against concentration range of 2.0-60.0 and 1.0-30.2 µg/mL for naproxen and rabeprazole sodium, respectively, a good correlation coefficient was obtained. For the equation of calibration curve, correlation coefficient ($R^2$) was obtained as 0.999 and 0.999 for naproxen and rabeprazole sodium, respectively and which was within the acceptable limit and it showed good linear relationship of the newly developed methods. The slope (m) and intercept (c) of the calibration curve were found to be 31319, 211.7 and 40497, 13992 (Figure 3) for naproxen and rabeprazole sodium, respectively (Table 3).

### Table 3: Linearity and range of the HPLC method.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Naproxen</th>
<th>Rabeprazole Sodium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linear concentration range (µg/mL)</td>
<td>2.0 - 60.0</td>
<td>1.0 - 30.2</td>
</tr>
<tr>
<td>Correlation coefficient ($R^2$)</td>
<td>0.999</td>
<td>0.999</td>
</tr>
<tr>
<td>Slope (m)</td>
<td>31319</td>
<td>40497</td>
</tr>
<tr>
<td>Intercept (c)</td>
<td>211.7</td>
<td>13992</td>
</tr>
<tr>
<td>SE of intercept</td>
<td>8649.70</td>
<td>7561.87</td>
</tr>
</tbody>
</table>

### Linearity and range

The precision of the method has been shown in Table 4. The intraday precision (% RSD) of naproxen and rabeprazole sodium was in the range of 0.39 - 1.88% and 0.20 - 1.51% while the interday precision was in the range of 0.08 - 1.34% and 0.73 - 0.87%, respectively.

### Table 4: Precision of the HPLC method.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Injected concentration (µg/mL)</th>
<th>Concentration found (µg/mL)</th>
<th>Precision (% RSD)</th>
<th>Concentration found (µg/mL)</th>
<th>Precision (% RSD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naproxen</td>
<td>10.0</td>
<td>10.4</td>
<td>1.3</td>
<td>10.3</td>
<td>1.3</td>
</tr>
<tr>
<td></td>
<td>20.0</td>
<td>19.7</td>
<td>1.9</td>
<td>20.2</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>40.0</td>
<td>40.6</td>
<td>0.4</td>
<td>38.9</td>
<td>0.1</td>
</tr>
<tr>
<td>Rabeprazole sodium</td>
<td>5.1</td>
<td>5.3</td>
<td>1.5</td>
<td>4.9</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>10.1</td>
<td>10.6</td>
<td>0.2</td>
<td>10.2</td>
<td>0.9</td>
</tr>
<tr>
<td></td>
<td>20.2</td>
<td>19.9</td>
<td>1.2</td>
<td>20.0</td>
<td>0.7</td>
</tr>
</tbody>
</table>

### Accuracy

The accuracy of the method was found to be in the range of 99.4-104.2% and 98.1-100.6% for naproxen and rabeprazole sodium, respectively. The result of accuracy is presented in Table 5.

### Table 5: Accuracy of the HPLC method.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Injected concentration (µg/mL)</th>
<th>Concentration found (µg/mL)</th>
<th>Accuracy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naproxen</td>
<td>32.0</td>
<td>33.3</td>
<td>104.2</td>
</tr>
<tr>
<td></td>
<td>36.0</td>
<td>35.8</td>
<td>99.5</td>
</tr>
<tr>
<td></td>
<td>40.0</td>
<td>39.7</td>
<td>99.4</td>
</tr>
<tr>
<td></td>
<td>44.0</td>
<td>44.3</td>
<td>100.7</td>
</tr>
<tr>
<td></td>
<td>48.0</td>
<td>47.9</td>
<td>99.7</td>
</tr>
<tr>
<td>Rabeprazole sodium</td>
<td>16</td>
<td>15.7</td>
<td>98.1</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>18.1</td>
<td>100.3</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>20.1</td>
<td>100.6</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>21.8</td>
<td>99.1</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>23.9</td>
<td>99.4</td>
</tr>
</tbody>
</table>

Since all the values of accuracy and % RSD of precision study were within the acceptable range, the results indicated that the method is reliable, reproducible and accurate.

### Limit of detection (LOD)

The LOD of naproxen and rabeprazole sodium was found to be 0.6 and 0.1 µg/mL, respectively.

### Limit of quantification (LOQ)

The LOQ of naproxen and rabeprazole sodium was found to be 1.7 and 0.4 µg/mL, respectively.

### Stability of sample solution

In the stability study, the sample solution was found to be stable for at least up to three hours. The result obtained is shown in Table 6.

### Table 6: Stability study of sample solution.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Injected concentration (µg/mL)</th>
<th>Concentration found (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 hour</td>
<td>1 hour</td>
</tr>
<tr>
<td>Naproxen</td>
<td>20.0</td>
<td>19.2</td>
</tr>
<tr>
<td></td>
<td>30.0</td>
<td>29.6</td>
</tr>
<tr>
<td></td>
<td>40.0</td>
<td>40.6</td>
</tr>
<tr>
<td>Rabeprazole sodium</td>
<td>10.0</td>
<td>10.6</td>
</tr>
<tr>
<td></td>
<td>15.0</td>
<td>15.5</td>
</tr>
<tr>
<td></td>
<td>20.0</td>
<td>20.9</td>
</tr>
</tbody>
</table>
Application of the developed method

The assay result of synthetic mixtures of marketed naproxen and rabeprazole sodium brands available in Bangladesh were ranged from 99.5 to 103.5% and 90.4 to 100.9%, respectively. The results are presented in Table 7.

Table 7: Assay of marketed formulations.

<table>
<thead>
<tr>
<th>Combination</th>
<th>Potency of Naproxen, N (%)</th>
<th>Potency of Rabeprazole, R (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N1 &amp; R1</td>
<td>103.5</td>
<td>100.4</td>
</tr>
<tr>
<td>N2 &amp; R1</td>
<td>103.5</td>
<td>100.4</td>
</tr>
<tr>
<td>N3 &amp; R2</td>
<td>103.5</td>
<td>96.9</td>
</tr>
<tr>
<td>N4 &amp; R3</td>
<td>103.5</td>
<td>90.4</td>
</tr>
<tr>
<td>N4 &amp; R2</td>
<td>103.0</td>
<td>99.5</td>
</tr>
</tbody>
</table>

CONCLUSION

The novelty of the work is the development of a simple, rapid, accurate, precise, reproducible and selective HPLC method for the single and simultaneous analysis of naproxen and rabeprazole sodium in pharmaceutical dosage form. The successful application of the developed method warrants that the method will be a valuable addition in the quality control department of pharmaceutical industry as it will reduce the analysis time and cost greatly.

Financial support and sponsorship: Nil.

Conflict of Interests: There are no conflicts of interest.

REFERENCES


How to cite this article: